Slingshot members are tracking this event:

Eli Lilly's (LLY) Galcanezumab Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache Data Presented

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Clinical Data
The episodic cluster headache study included a two-month treatment period comparing galcanezumab to placebo. Patients with episodic cluster headache treated with galcanezumab (300 mg once-monthly) experienced statistically significant differences in the reduction of weekly cluster headache attacks compared to patients treated with placebo across weeks one to three of the two-month, double-blind treatment period (-8.7 for galcanezumab compared to -5.2 for placebo, p=0.036), the primary endpoint of the study.In May 2017, Lilly announced positive data from three Phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) evaluating galcanezumab for the treatment of chronic and episodic migraine. In these studies, galcanezumab demonstrated statistically significant reductions in the number of monthly migraine headache days compared to placebo at both studied doses (120 mg and 240 mg once-monthly).
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 15, 2018
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Galcanezumab, Episodic Cluster Headache